



**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)
REDEEMER'S UNIVERSITY**

**AUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER, 2017**

**BBC PROFESSIONALS
(Chartered Accountants)**

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)
REDEEMER'S UNIVERSITY**

**AUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER, 2017**

CONTENTS	PAGES
General Information	2
Report of the Centre Officials	3
Report of the Independent Auditors	5
Income Statement	7
Statement of Financial Position	8
Statement of Cashflows	9
Notes to the Financial Statements	10
Statement of Value Added	14
Schedules to the Financial Statements	15

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)
REDEEMER'S UNIVERSITY**

AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER, 2017

GENERAL INFORMATION

PROJECT CENTRE OFFICIALS

Prof. Christain Happi	-	Center Director
Dr. Folarin Onikepe	-	Deputy Director
Mr. Adebayo Amao	-	Project Manager
Mr. Afolabi Idowu	-	Project Accountant
Banjo Adeyemi A. (Mrs)	-	Project Internal Auditor
Osilaja Lucy O. (Mrs)	-	Procurement Officer
Mr. Edevo Meshack	-	Finance Officer

DIRECTORATE OF INTERNAL AUDIT

Akinlawon O. Kikelomo (Mrs)	-	Principal Internal Auditor
-----------------------------	---	----------------------------

UNIVERSITY PRINCIPAL OFFICERS

Professor Z. Debo Adeyewa	-	Vice Chancellor
Professor Kayode S. Adekeye	-	Deputy Vice Chancellor
Mrs. Bolatito A. Oloketuyi	-	Registrar
Mr. Samuel A. Momodu	-	Ag. Bursar
Dr. Emmanuel L. Adebayo	-	University Librarian

INDEPENDENT AUDITORS

BBC Professionals
(Chartered Accountants)
Charter House
7 McNeil Road
Sabo Yaba
Lagos

BANKERS

Diamond Bank Plc
Zenith Bank Plc

OPERATING OFFICE

Redeemer's University
African Centre of Excellence for
Genomics of Infectious Diseases (ACEGID)
P.M.B 230, Ede
Osun State

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Report of the Project Officials

For the year ended 31 December, 2017

The Centre is pleased to present their report together with the financial statements of the Project for the year ended 31 December, 2017.

1. **VISION**

To constitute a strong force in support of the research on the study of humans and microbes to transform the clinical care, surveillance and understanding of infectious diseases.

2. **PROJECT OBJECTIVES**

The objectives of the Project are as follows:

- a) To develop a critical mass of well-trained African genomics scientists;
- b) To empower African researchers to utilize genomics-based tools towards the control and elimination of infectious diseases;
- c) To create genomics curricula to support and promote cutting-edge genomics-based research;
- d) To engage communities in prevention efforts and public health education; and
- e) To contribute to the improvement of global public health and economic development.

3. **RESULT FOR THE YEAR**

Income	N 747,850,552
Less: Expenditure	(350,591,589)
	<hr/>
Excess of income over expenditure	397,258,963 =====

4. **EVENTS AFTER REPORTING PERIOD**

There are no material events after the reporting period that will affect these financial statements.

5. **EMPLOYMENT OF DISABLED PERSONS**

It is the center's policy that there should be no discrimination in considering applications for employment including those from disabled persons. All employees whether or not disabled are given equal opportunities to develop.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Report of the Project Officials

For the year ended 31 December, 2017

6. PROJECT OFFICIALS

The project officials are responsible for the preparation of the financial statements which give a true and fair view of the state of affairs, and of the result for the year and in compliance with the International and Local Standard/Regulations.

They are obliged to ensure that:

- Proper accounting records are maintained;
- Internal control measures are instituted which, as far as is reasonably possible, safeguard the assets;
- Actions are taken to prevent and detect fraud and other irregularities;
- Applicable accounting standards are followed;
- Suitable accounting policies are adopted and consistently applied;
- Judgements and estimates made are reasonable and prudent, and
- The going-concern basis is used, unless it is inappropriate to presume that the center will continue in operation.

7. INDEPENDENT AUDITORS

Messrs BBC Professionals (Chartered Accountants) have indicated their willingness to continue in office. In accordance with Section 357(2) of the Companies and Allied Matters Act CAP C20 LFN 2004, the project officials are authorised to consider the re-appointment of the Auditors.

BY ORDER OF THE PROJECT OFFICIALS

Prof. Christain Happi
Centre Director

Osun, Nigeria

2018

**REPORT OF THE INDEPENDENT AUDITORS TO THE OFFICIALS OF
AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

We have audited the accompanying financial statements of African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) set out on pages 7 to 13 which comprise the Statement of Financial Position as at 31 December, 2017, the income statement and statement of cash flows for the year then ended, the summary of significant accounting policies and explanatory notes.

In our opinion, the financial statements give a true and fair view of the financial position of African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) as at 31 December, 2017 and of its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Companies and Allied Matters Act CAP C20 LFN 2004, and the Financial Reporting Council of Nigeria Act, No 6 2011.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Centre in accordance with the Institute of Chartered Accountants of Nigeria (ICAN) Professional Code of Conduct and Guide for Accountants, which is consistent with the International Ethics Standards Board for Accountants Code of Ethics for Professional Accountants (Part A and B), together with other ethical requirements that are relevant to our audit of the financial statements in Nigeria, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Project Officials are responsible for the other information. The other information refer to the Officials' Report as required by the Companies and Allied Matters Act CAP C20 LFN 2004, which we obtained prior to the date of this auditor's report. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Project Officials for the Financial Statements

The Project Officials are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards and the requirements of the Companies and Allied Matters Act CAP C20 LFN 2004, Financial Reporting Council of Nigeria Act No 6, 2011, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Centre's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Officials either intend to liquidate the Centre to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Centre's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Centre Officials.
- Conclude on the appropriateness of the Officials' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Centre's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Centre to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We also provided those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

In accordance with the Sixth Schedule of Companies and Allied Matters Act CAP C20 LFN 2004, we expressly state that:

- i We have obtained all the information and explanation which to the best of our knowledge and believe were necessary for the purpose of our audit;
- ii The Centre has kept proper books of account, so far as appears from our examination of those books; and
- iii The Centre's statement of financial position and its income statement are in agreement with the books of account and returns.

Lagos, Nigeria

2018

Everestus Itodo, FCA
FRC/2013/ICAN/0000002513

For: **BBC PROFESSIONALS**
Chartered Accountants

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Income Statement

For the year ended 31 December, 2017

	Notes	2 0 1 7 N	2 0 1 6 N
INCOME	5	747,850,552	1,026,735,355
EXPENDITURE:			
Salaries and wages		16,790,322	20,423,683
Advertisement and publicity		1,511,732	2,331,600
Seminars and courses		38,715,740	48,138,564
ACE meetings and workshop		9,983,031	14,744,812
Genomics foundational training		1,689,285	-
Printing and stationery		1,125,950	434,320
Air fare		1,750,489	2,073,171
Internet connectivity		-	6,000
I.T expenses		437,500	621,850
Cleaning		1,299,876	784,402
Electricity & lighting		3,606,650	1,290,330
Telephone and postages		213,395	117,100
Transport		777,856	577,446
Entertainment		533,765	290,451
Bank charges		670,103	270,753
Hotel expenses		847,605	1,109,237
Repairs and maintenance		1,992,862	1,061,615
Motor vehicle running		2,988,555	1,371,393
Exchange difference		12,544,646	(50,555)
Lab consumables		42,430,992	2,172,862
Audit fees		500,000	500,000
Depreciation		30,156,986	5,835,338
H3 Africa expenses		44,372,119	319,092,059
NIH expenses		3,385,860	12,887,146
JWARG expenses		132,266,270	-
		350,591,589	436,083,575
Surplus transferred to Accumulated Fund	7	397,258,963	590,651,780

Note: The explanatory notes on pages 10 to 13 are to be read with these financial statements.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Statement of Financial Position

As at 31 December, 2017

	Notes	2 0 1 7 N	2 0 1 6 N
ASSETS:			
NON-CURRENT ASSETS	4	204,207,924	184,027,911
CURRENT ASSETS			
Cash and Cash Equivalents	8	751,230,553	488,440,497
Other Receivables	9	25,205,680	17,987,750
NET ASSETS		980,644,157 =====	690,456,158 =====
FUND AND LIABILITY:			
Accumulated fund	7	979,365,051	582,106,088
Payables	6	1,279,106	108,350,070
		980,644,157 =====	690,456,158 =====

Note: The explanatory notes on pages 10 to 13 are to be read with these financial statements.

The financial statements were approved by the Officials on 2018 and signed on its behalf by:

Professor Christain Happi
Project Director

Mr Afolabi Idowu
Project Accountant

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Statement Of Cash Flows

For the year ended 31 December, 2017

Notes	2 0 1 7 N	2 0 1 6 N	
CASHFLOWS FROM OPERATING ACTIVITIES			
Excess of income over expenditure	7	397,258,963	590,651,780
Adjustments for non-cash items:			
Depreciation	4	30,156,986	5,835,338
Cashflow before changes in working capital		<u>427,415,949</u>	<u>596,487,118</u>
Changes in Working Capital			
Changes in payables	6	(107,070,964)	(47,609,106)
Changes in receivables	9	(7,217,930)	(17,987,750)
INVESTING ACTIVITIES			
Purchase of Non-current Assets	4	(50,336,999)	(179,714,651)
Net increase in cash and cash equivalents		<u>262,790,056</u>	<u>351,175,611</u>
Cash and cash equivalents as at 1 January		<u>488,440,497</u>	<u>137,264,886</u>
Cash and cash equivalents as at 31 December	8	<u>751,230,553</u> =====	<u>488,440,497</u> =====

Note: The explanatory notes on pages 10 to 13 are to be read with these financial statements.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements

For the year ended 31 December, 2017

1. Reporting Entity

African Centre of Excellence For Genomics and Infectious Diseases (ACEGID) is an international capacity building project with Centres all over the West African countries :- Senegal, Sierra Leone, Nigeria etc and the headquarter is situated at Redeemer's University, Ede in Osun State, Nigeria.

The mandate of this Centre primarily is to train Students on a regional basis and as well help in infectious diseases diagnoses, its controls and preventions. An average of 23 PhD Students and 173 Masters Degree Students are expected to be trained in the region. The Centre has a life span of four years starting from year 2014 to year 2018.

2. Basis of presentation and compliance with IFRSs

The Centre's financial statements for the year ended 31 December, 2017 are prepared and presented in accordance with, and comply with International Financial Reporting Standard (IFRS) and International Financial Reporting Interpretation Committee (IFRIC) interpretations issued and effective for the period presented.

These financial statements comprise income statement, statement of financial position, the statement of cash flows, the accounting policies and the explanatory notes. The financial statements have been prepared in accordance with the going concern principle which is measured at fair value.

The financial statements are presented in Naira, which is the Centre's presentational currency. The figures shown in the financial statements are stated to the nearest Naira.

The cash flows from operating, investing and financing activities are determined by using the indirect method.

3. Significant accounting policies

The accounting policies set out below have been applied in these financial statements unless otherwise indicated.

Basis of Accounting

The accounts are prepared under the historical cost convention.

Foreign Currencies

Account balances in foreign currencies are converted to Naira at the rates ruling at the Statement of financial position date.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements

For the year ended 31 December, 2017

Non-Financial Assets

Non-Financial Assets are stated at cost or valuation less accumulated depreciation and will be tested for impairment in compliance with IFRS where there are indications to do so.

Depreciation

Depreciation is provided on the straight line basis at the following rates, calculated to write-off the cost of the assets over their estimated useful lives:

Land	-	0%
Buildings Improvement	-	10%
IT Equipment	-	12.5%
Furniture and Fittings	-	12.5%
Office Equipment	-	12.5%
Labouratory Equipment	-	12.5%
Guest House Equipment	-	12.5%
Plant and Machinery	-	15%

Impairment

Impairment test will be carried out on all non-financial assets subject to management discretion so as to ensure that assets are not maintained at more than their recoverable amount which is the higher of fair value less cost of disposal and value in use.

Payables

Payables are recognised at the completion of supplies, projects or jobs.

Taxation

The Centre is a non-profit making organisation, hence its not liable to taxation.

Investment Income

Interest income are accounted for in the year they are received.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements

For the year ended 31 December, 2017

		2 0 1 7	2 0 1 6
		N	N
5. INCOME			
	Grant received from World Bank (Note 5.1)	324,550,092	503,133,966
	Interest on bank accounts	2,304,424	3,966,101
	Income from students tuition fees	7,379,000	17,069,000
	Income from other funds (Note 5.2)	413,617,036	502,566,288
		<u>747,850,552</u>	<u>1,026,735,355</u>
		=====	=====
.1	The grant received from world bank totalling N324,550,092 was both in cash and through payment for Research Equipment.		
.2	Income from other funds was received from NIH to support research on malaria and also from H3 Africa and JWARG to support general research on infectious diseases.		
	Funding from NIH	-	19,629,288
	Funding from JWARG	133,081,504	60,900,000
	Funding from H3 Africa	278,393,948	422,037,000
	IGR-Registration fees	2,141,583	-
		<u>413,617,036</u>	<u>502,566,288</u>
		=====	=====
6. PAYABLES			
	Accrued audit fees	500,000	500,000
	Redeemer's University	-	10,608,991
	H3 Africa Project (Diamond Bank Dom)	-	30,620,963
	H3 Africa Project (Zenith Bank Dom)	-	66,450,939
	Unremitted Withholding Taxes	772,106	167,577
	Other Payables	7,000	1,600
		<u>1,279,106</u>	<u>108,350,070</u>
		=====	=====
7. ACCUMULATED FUND			
	At 1 January	582,106,088	(8,545,692)
	Surplus for the year	397,258,963	590,651,780
		<u>979,365,051</u>	<u>582,106,088</u>
		=====	=====
8. CASH AND CASH EQUIVALENTS			
	Cash	-	825,600
	Diamond Bank Current Account-NGN	2,696,676	35,276,633
	Diamond Bank H3 Africa Current Account-NGN	31,875,380	-
	Diamond Bank JWARG Current Account	16,176,850	-
	Diamond Bank Current Account-Dom	312,478,231	277,920,292
	Diamond Bank JWARG Account-Dom	68,077,611	60,903,328
	Diamond Bank H3 Africa Account-Dom	316,547,806	106,772,502
	Diamond Bank NIH Account-Dom	3,377,999	-
	Zenith Bank NIH Account-Dom	-	6,742,142
		<u>751,230,553</u>	<u>488,440,497</u>
		=====	=====
9. OTHER CURRENT ASSETS			
	Receivable from H3 Africa	-	918,750
	Receivable from Redeemer's University Of Nigeria	24,448,000	17,069,000
	Cash advance	757,680	-
		<u>25,205,680</u>	<u>17,987,750</u>
		=====	=====
10. CONTINGENT LIABILITIES			
	There were no known contingent liabilities in respect of legal actions against the Centre for the year ended 31 December, 2017.		

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements
For the year ended 31 December, 2017

4. PROPERTY, PLANT AND EQUIPMENT

	PLANT AND MACHINERY	BUILDING IMPROVEMENTS	IT EQUIPMENT	FURNITURE & FITTINGS	OFFICE EQUIPMENT	LABORATORY EQUIPMENT	GUEST HOUSE EQUIPMENT	TOTAL
COST	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=
At 1 January, 2017	-	17,550,021	2,966,376	11,174,000	10,169,720	148,670,753	1,424,140	191,955,010
Additions	12,476,015	106,600	7,023,599	1,154,486	234,000	28,522,299	820,000	50,336,999
At 31 December, 2017	12,476,015	17,656,621	9,989,975	12,328,486	10,403,720	177,193,053	2,244,140	242,292,009
DEPRECIATION								
To 1 January, 2017	-	1,774,792	435,462	2,440,275	1,364,190	1,734,362	178,018	7,927,099
Charge for the year	1,871,402.18	1,765,662	1,248,747	1,541,061	1,300,465	22,149,132	280,518	30,156,986
To 31 December, 2017	1,871,402	3,540,454	1,684,209	3,981,336	2,664,655	23,883,494	458,535	38,084,085
NET BOOK VALUE								
At 31 December, 2017	10,604,612	14,116,167	8,305,766	8,347,150	7,739,065	153,309,559	1,785,605	204,207,924
At 31 December, 2016	-	15,775,228	2,530,914	8,733,725	8,805,530	146,936,392	1,246,123	184,027,911

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Statement of Value Added

For the year ended 31 December, 2017

	2 0 1 7 N %	2 0 1 6 N %
Income	747,850,552	1,026,735,355
Cost of materials and services	(303,644,280)	(409,824,554)
Value Added	444,206,272 100 ===== ===	616,910,801 100 ===== ===
Applied as follows:		
To pay employees		
Salaries and Wages	16,790,322 4	20,423,683 3
Future expansion		
Depreciation	30,156,986 7	5,835,338 1
Excess of income over expenditure	397,258,963 89	590,651,780 96
Value Added	444,206,272 100 ===== ===	616,910,801 100 ===== ===

Value added shows the additional fund generated in the year by ACEGID to the Centre through the efforts of the Trustees and Employees and how this new fund was distributed with portion retained in the Centre for future development.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Schedules to the financial statements

For the year ended 31 December, 2017

LIST OF MATERIAL ASSETS		=N=
1. BUILDING IMPROVEMENT		
Labouratory renovation		10,441,030
Plumbing works		3,085,670
Electrical works		3,085,670
Partitioning with board and glass		592,250
Flowers and lawn		345,400
		17,550,020
		=====
2. IT EQUIPMENT		
HP Desktop computer		115,000
Multi media Projector		1,637,950
Installation of CCTV camera		954,765
Canon EOS Mark III DSLR Camera		1,007,432
Mac Computers		5,916,417
		9,631,564
		=====
3. FURNITURE AND FITTINGS		
Quarter window blinds		235,620
Cashier seats for labouratory		1,152,000
Office furniture		3,385,000
Cupboard, white board & notice board		95,000
Glass office tables		1,473,380
Labouratory chairs		178,900
Shelves		480,000
		6,999,900
		=====
4. OFFICE EQUIPMENT		
Thermocool chest freezer		69,900
Samsung refrigerator		95,000
1.5 HP panasonic split AC (28)		3,176,500
10KW/480 hybrid voltron inverter		3,000,000
Fridge		96,000
Installation of solar panel		3,129,500
Glass office tables		76,420
File cabinet		34,000
Rexel shredder		45,000
Thermocool Fridge HR - 107		45,000
		9,767,320
		=====
5. LABORATORY EQUIPMENT		
Thermo Scientific1284 biological safety cabinet		45,940,718
Mi Seq FGxTM sequencing system machine		95,821,588
Liquid Nitrogen tank		5,115,600
		146,877,906
		=====
6. PLANT AND MACHINERY		
Cummins Generator		12,476,015
		=====